A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms EAST
- Sponsors AbbVie
- 18 Nov 2021 Status changed from active, no longer recruiting to completed.
- 22 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2020 Planned End Date changed from 14 Mar 2020 to 30 Jun 2021.